Why the study?
Diabetic nephropathy is one of the most serious complications of diabetes mellitus, prompting the need to critically discuss available data on its pharmacological management.
Do pharmacological agents like RAS inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists improve outcomes in patients with diabetic nephropathy?
Do pharmacological agents like RAS inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists improve outcomes in patients with diabetic nephropathy?
This review highlights the cornerstone role of RAS inhibitors and the promising benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in managing diabetic nephropathy and reducing cardiovascular events.
Authors
No takes yet. Share an insight, caveat, or question.
Supports guideline-directed management of diabetic nephropathy; leaves open optimal combinations, sequencing, and staging in prospective trials.
Papademetriou et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: